Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CanniMed 22.1
- Development stage
- Unknown
- Lead developer
- Aurora Cannabis
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
CanniMed 22.1 is a medical cannabis product developed by CanniMed (now a subsidiary of Aurora Cannabis). It consists of a hybrid blend of pre-milled dried cannabis flower standardized for dose consistency. The product is characterized by a high THC to CBD ratio, containing approximately 22% tetrahydrocannabinol (THC) and 1% cannabidiol (CBD). As a cannabinoid-based therapy, it exerts its effects by interacting with the endocannabinoid system, specifically acting as an agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). It is primarily indicated for the management of chronic pain, inflammation, and chemotherapy-induced nausea and vomiting. CanniMed was Canada's first licensed medical cannabis producer, and this product is currently marketed through the Aurora Medical division.
- Brand names
- CanniMed 22.1CanniMed22.1CanniMed-22.1
- Other names
- CanniMed 22:1
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on CanniMed 22.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanniMed 22.1.